Skip to main content

Day: June 9, 2021

New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

Adaptive’s immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when neutralizing antibodies are diminished SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that immunoSEQ® T-MAP™ COVID was used in the Nature study to measure the T-cell immune response elicited by the Johnson & Johnson COVID-19 vaccine in the context of multiple variants of SARS-CoV-2, including B 1.351 and B.1.1.7. The study provides further evidence that the T-cell response may contribute to protection from COVID-19. Adaptive’s Technology was used...

Continue reading

KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021

CELEBRATION, Fla., June 09, 2021 (GLOBE NEWSWIRE) — KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its expected addition to the broad-market Russell 3000® Index and the Russell 2000® Index in accordance with the 2021 Russell indexes annual reconstitution.  KemPharm’s anticipated inclusion in the Russell indexes will be effective after the U.S. market opens on Monday, June 28, 2021. “The expected addition of KemPharm to the Russell indexes is the latest milestone during what has been a truly transformational year for the Company. In just the last six months, we have received FDA approval for our lead drug candidate AZSTARYS™, completed a series of financial transactions that allowed KemPharm to up-list our stock to The Nasdaq...

Continue reading

VitalHub Announces Sale to University Hospitals Coventry and Warwickshire NHS Trust

TORONTO, June 09, 2021 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the recent sale of subsidiary Intouch with Health’s (“Intouch”) digital health platform to University Hospitals Coventry and Warwickshire NHS Trust (the “Trust” or “Coventry and Warwickshire”) and an expansion sale following a successful proof-of-concept installation. Coventry and Warwickshire is one of the UK’s largest teaching Trusts and is responsible for managing two major hospitals in Coventry and Rugby, serving a population of over 1 million people and providing more than 800,000 episodes of care to patients. The Trust principal teaching hospital for Warwick Medical School, with whom it works in close partnership with to develop innovative medical education programmes and clinical research. The Trust...

Continue reading

Adamis Provides Update on ZIMHI™

FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021 SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for ZIMHI™, which is its higher naloxone injection product candidate for the treatment of opioid overdose. Adamis received FDA correspondence relating to the Company’s NDA, stating that the Agency had completed its filing review and had determined that the NDA was sufficiently complete to permit a substantive review. The FDA also provided a target action date under the Prescription Drug User Fee Act (PDUFA date) of November 12, 2021. “We are pleased with the FDA’s decision to accept for review...

Continue reading

US Energy Initiatives Examines Multiple Opportunities Including a Gold and Silver Opportunity

WOODLAND HILLS, CA, June 09, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — US Energy Initiatives Corp, Inc. (OTC PINK:USEI) is pleased to announce that management has been investigating a number of business ventures that can bring significant shareholder value to the stockholders of the company. Management also invites shareholders to review an interview done this week with the company’s CEO that is informative @ https://recordings.tapeacall.com/t/heCIZr_MEpKA According to Anthony K. Miller, CEO, “Over the course of the last two months management has been investigating opportunities that it feels will become significant ventures for the company, and the most notable is a project in the gold and silver mining industry (obviously we will explain the deal better once we get closer to a close). Management is planning to leverage...

Continue reading

Reyna Silver Quadruples Claim Package at Medicine Springs and Announces 2021 Exploration Program Underway

Figure 1Medicine Springs Joint Venture Mineral ClaimsVANCOUVER, British Columbia and HONG KONG, June 09, 2021 (GLOBE NEWSWIRE) — Reyna Silver Corp. (TSXV: RSLV; OTCQB: RSNVF; FRA: 4ZC) (“Reyna”) announces that it has added 450 unpatented Federal mineral claims covering 3,642 hectares to its Medicine Springs Property located in the Ruby Mountains Valley in Elko County, Nevada. Medicine Springs shows many of the earmarks of a significant Carbonate Replacement Deposit (CRD) similar to the Santa Eulalia District in Chihuahua Mexico which hosts Reyna’s Guigui Project. Combined with the original 149 claims (1,189 ha) optioned from Northern Lights Resources Corp. (CSE: NLR) in 2020 (see press release of October 5, 2020) the property now consists of 599 contiguous claims covering 4,831 hectares, which covers the expanded...

Continue reading

Aedifica NV/SA: Issuance of up to 2,800,000 New Shares via an accelerated bookbuilding with international institutional investors

Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding the issuance of up to 2,800,000 New Shares via an accelerated bookbuilding with international institutional investors. Please access the attachments by clicking on the link below and by accepting the disclaimer. Press release EN Communiqué de presse FR Persbericht NL

Continue reading

Auxly Announces $15.0 Million Bought-Deal Public Offering

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, June 09, 2021 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (“Auxly” or the “Company”) (TSX: XLY) (OTCQX: CBWTF) is pleased to announce that it has entered into an agreement pursuant to which ATB Capital Markets Inc. (“ATB”), as sole bookrunner, and Cantor Fitzgerald Canada Corporation, acting as co-lead underwriters of the Offering, together with a syndicate of underwriters (collectively, the “Underwriters”), will purchase 47,620,000 Units of the Company (the “Units”), on a bought-deal basis at a price per Unit of $0.315 (the “Issue Price”) for gross proceeds of $15,000,300 (the “Offering“). A.G.P./Alliance Global Partners is acting as the sole U.S. sub-agent and financial advisor to the Company in connection with the Offering...

Continue reading

TECH MAHINDRA INKS AGREEMENT WITH VSBLTY & INTEL TO CREATE THE FIRST DIGITAL IN-STORE MEDIA NETWORK THROUGHOUT LATIN AMERICA

Philadelphia, PA, June 09, 2021 (GLOBE NEWSWIRE) — VSBLTY Groupe Technologies Corp. (CSE:VSBY) (Frankfurt 5VS) (OTC:VSBGF) (“VSBLTY”), a leading software provider of security and retail analytics technology, and Tech Mahindra, a leading provider of digital transformation, consulting and business re-engineering services, today announced the signing of a four-year agreement to manage services for roll out, operations and analytics related to Intel/VSBLTY video cameras, screens and hardware required to establish the first international digital in-store media network in more than 50,000 Modelorama stores and neighborhood bodegas throughout Latin America. The project, which also includes Mexico’s Grupo Modelo (part of the AB InBev family of companies) Intel® Corporation and Retailigent Media, will create the largest digital in-store...

Continue reading

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021

ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in two upcoming investor conferences in June 2021: JMP Securities Life Sciences ConferenceFireside ChatWednesday, June 16, 2021 at 1:00 pm ET Raymond James Human Health Innovations ConferenceFireside ChatWednesday, June 23, 2021 at 8:40 am ET A link to the live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.